This morning, the EU regulators cleared pembro-, as a first line lung cancer treatment -- and the sales in Europe are going to accelerate appreciably. True, the price point is lower, on a per patient treated basis, than the comparable US regimen's prevailing reimbursed rate, but lung cancer is the highest burden cancer in all of the EU. So this is quite good news.
Increasing channel volume uptake highly likely, now -- from the presser of this morning:
. . . .Merck today announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of adults with metastatic squamous non-small cell lung cancer (NSCLC). This approval is based on data from the Phase 3 KEYNOTE-407 trial, which demonstrated that KEYTRUDA in combination with chemotherapy significantly improved overall survival (OS) in adults with metastatic squamous NSCLC regardless of PD-L1 tumor expression status, reducing the risk of death by 36 percent compared to chemotherapy alone (HR=0.64 [95% CI, 0.49-0.85]; p=0.0008).
“In KEYNOTE-407, first-line treatment with KEYTRUDA in combination with chemotherapy resulted in significant improvements in overall survival for patients with metastatic squamous non-small cell lung cancer, regardless of PD-L1 expression,” said Dr. Luis Paz-Ares, chair of the medical oncology department, Hospital Universitario Doce de Octubre, Madrid, Spain. “Lung cancer is the leading cause of cancer death in Europe, so this approval marks an important milestone for the patients and families facing this difficult-to-treat type of lung cancer.”. . .
Now you know -- sourced my pie -- it's in office fridge, ready for 1:59, on the dot. Smile. . . . UPDATED: A Boulder Colorado SOHO (and NASA Ames Research Center) gif, for the day:
नमस्ते
No comments:
Post a Comment